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Abstract
Background: Currently, there is a lack of guidelines for the use of short-acting bronchodilators (SABD) in people
admitted to hospital for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), despite routine use
in practice and risk of cardiac adverse events.
Aim: To review the evidence that underpins use and optimal dose, in terms of risk versus benefit, of SABD for
inpatient management of AECOPD and collate the results for future guidelines.
Methods: Medline, Embase, the Cochrane Central Register of Controlled Trials, clinicaltrials.gov and International
Clinical Trials Registry Platform were searched (inception to November 2017) for published and ongoing studies.
Included studies were randomised controlled trials or controlled clinical trials investigating the effect of SABD (β2-
agonist and/or ipratropium) on inpatients with a diagnosis of AECOPD. This review was undertaken in accordance
with PRISMA guidelines and a pre-defined protocol. Due to heterogeneous methodologies, meta-analysis was not
possible so the results were synthesised qualitatively.
Results: Of 1378 studies identified, 10 met inclusion criteria. Narrative synthesis of 10 studies revealed no significant
differences in most outcomes of interest relative to dose, delivery via inhaler or nebuliser, and type of β2-agonist
used. However, some evidence demonstrated significantly increased cardiac side effects with increased dosage of
β2-agonist (45% versus 24%), P<0.05).
Conclusion: This review identified a paucity of methodologically rigorous evidence evaluating use of SABD among
AECOPD. The available evidence did not identify any additional benefits for participants receiving higher doses of
short-acting β2-agonists compared to lower doses, or based on type of delivery method or β2-agonists used.
However, there was a small increase in some adverse events for participants using higher doses of β2-agonists.
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Introduction
The high prevalence of cardiac comorbidity and cardiac
death in people with chronic obstructive pulmonary dis-
ease (COPD) [1, 2] may be exacerbated by the adrener-
gic effects of the routine frequent use of short-acting
bronchodilators in clinical practice [3]. As a result,
current guideline recommendations are to avoid pro-
longed use of β2-agonists [4]. Hence, there is a need to
synthesise existing evidence for its use given that these
agents are a mainstay of COPD exacerbation manage-
ment, with some consideration of the risk/benefit, and
optimal dosing.
Periods of acute exacerbation of COPD (AECOPD)
often result in hospitalisation, wherein patients are at in-
creased risk of decreased quality of life and death [5–8].
People suffering AECOPD experience an abnormal de-
terioration of respiratory symptoms defined as increased
dyspnoea, sputum production and/or sputum purulence
which may be infective or non-infective in origin [7].
The severity of an exacerbation is, in part, determined
by the degree of dyspnoea experienced by the patient,
largely driven by bronchoconstriction [9]. It is a univer-
sally accepted practice to administer rescue doses of
short-acting β2-agonists and/or ipratropium known col-
lectively as short-acting bronchodilators (SABD) to re-
duce this bronchoconstriction in AECOPD [9, 10].
However, cardiac markers, N-terminal prohormone of
brain natriuretic peptide (NT-proBNP) and troponin T,
are noted to be elevated in people suffering AECOPD
and predict 30-day mortality independently of disease
severity and prognosis [11]. Furthermore, the high
prevalence of cardiovascular disease in people with
COPD is well documented; despite this, the common co-
morbidity remains largely underdiagnosed [1, 2, 12–19].
Hence, unregulated, frequent administration of SABD in
the hospital setting is concerning, given the adrenergic
and pro-arrhythmic effects. There is some evidence of
positive correlation between levels of short-acting
β2-agonists and increased cardiac stress markers, specif-
ically NT-proBNP [20].
Despite routine administration of SABD in the in-
patient setting and the potential risk, there is no clearly
evidence-based, standardised guideline for their use, par-
ticularly in terms of optimal and safe dosage [21]. Differ-
ences in clinical practice can be extrapolated down from
geographic variances, between hospital differences and
the dissimilarities in practice between individual physi-
cians. Consultation of major international COPD guide-
lines provides little elucidation, with recommendations
for SABD being underpinned by weak evidence, some of
which has been extrapolated from studies of asthma pa-
tients and stable COPD [22, 23]. Overall, the evidence
supporting the use of SABD for inpatients is unspeci-
fied to the inpatient setting [7, 22, 23]. Given that
people with COPD are admitted to hospital frequently
[24–26], optimisation and standardisation of COPD
management, which includes SABD administration, is
important to address large variability identified in
current treatment [27, 28].
This systematic review was undertaken in order to
evaluate the existing literature relating to SABD use for
the inpatient management of AECOPD. Subsequently,
these findings may be used as the foundation for clinical
practice guidelines regarding specifications for the in-
patient administration of SABD, including the use of one
or a combination of agents, optimal and safe dose, most
effective delivery method and duration of treatment.
Methods
This systematic review was undertaken in accordance
with the guiding principles of the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement (see Additional file 1) [29]. Prior to
commencing the review, a protocol was defined by the
authors. This was not registered online in Prospective
Register of Systematic Reviews (PROSPERO), and there-
fore, the review protocol will be described in detail in
this section.
Eligibility criteria
Studies were eligible for inclusion if they were rando-
mised controlled trials or controlled clinical trials inves-
tigating the effect of SABD (short-acting β2-agonist and/
or ipratropium) when administered to adult inpatients
with a diagnosis of AECOPD. The comparison group
could be either placebo, usual care, delayed intervention
or another SABD (agent, dose or delivery method). Stud-
ies were included if the SABD was part of a wider treat-
ment regime. The protocol stipulated that a study may
be included if a maximum of 25% of the participants
had a primary diagnosis other than COPD (e.g. partici-
pant is asthmatic or has secondary diagnosis of
AECOPD) and if the data for COPD could be isolated.
This parameter was implemented in acknowledgement
of the high prevalence of comorbid conditions in pa-
tients with COPD [30–32]. Full-text and conference ab-
stracts were eligible for inclusion where relevant
outcomes were reported. In the case of abstracts with no
published full text, authors were contacted in an effort
to access more complete data for review.
Outcomes
The authors selected both primary and secondary out-
comes which were deemed to be the most clinically rele-
vant to the topic. The primary outcome was selected,
according to the clinical expertise of the clinician-authors,
as the primary consideration for use of SABD to treat
AECOPD in the hospital setting.
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The primary outcome in this review was treatment
failure. For the purposes of this review, this was defined
as (1) mortality as a result of AECOPD, (2) intensive
care unit/critical care unit (ICU/CCU) admission or (3)
respiratory failure requiring non-invasive or mechanical
ventilation. Secondary outcomes included spirometric
values, i.e. forced expiratory volume in 1 s (FEV1) and
forced vital capacity (FVC), dyspnoea, sputum produc-
tion/purulence and quality of life. Other outcomes of
interest were hospital utilisation (length of stay, hospital
admission/readmission rate, emergency department pre-
sentations) and adverse events related to β2-agonist and
anticholinergic agents (including cardiovascular events).
Search strategy
A keyword search strategy for systematic literature
searching was devised and refined after a preliminary
search by ZK and NS in consultation with a senior Ref-
erence Librarian, with the goal of identifying all relevant
studies (see example in Additional file 2). Both keywords
and MeSH terms were used where appropriate; hence, a
combination of the following was used: COPD, inpatient,
hospital and bronchodilator agents; all variants of these
terms were also included. Electronic databases searched
(all years up to 2017) for published literature were Med-
line (OVID), Embase (OVID) and the Cochrane Central
Register of Controlled Trials (CENTRAL). Grey litera-
ture was searched online via ClinicalTrials.gov and the
International Clinical Trials Registry Platform to identify
relevant ongoing studies. Supplementing this, alerts were
set for the searched databases to ensure any recently
published studies were identified prior to publishing this
review. Screened studies were not restricted by language
or date. Bibliographies of included articles and reviews
were hand searched for identification of any other stud-
ies potentially eligible for inclusion. Online searches are
current as of November 2017.
Data extraction
Screening was undertaken by two independent re-
viewers. First, titles and abstracts of identified citations
were appraised, after duplicates were removed. Following
this, full text was obtained for the remaining studies and
compared to the pre-established inclusion criteria, be-
fore final inclusion in the review. Data pertaining to the
above-mentioned primary and secondary outcomes as
well as participant and study design characteristics were
extracted into a standardised, pilot-tested form (see
Additional file 3). This was done independently by a
combination of two authors (ZK and either NS or OM).
If any disagreements had occurred during this process
that could not be resolved by consensus, a third member
of the author team would have been consulted.
Methodological quality
Consensus was reached regarding methodological qual-
ity of the included studies after independently evaluating
each of them in keeping with the Cochrane Collabora-
tion’s tool for assessing risk of bias [33]. Using this
method, each study was rated as having low, unclear or
high risk of bias for domains including “selection bias”,
which is split into two sub-groups relating to the appro-
priateness of the randomisation procedure and allocation
of participants to study groups. Presence of “perform-
ance bias” and “detection bias” relating to the blinding
of participants, personnel and outcome assessment was
also assessed, in addition to “attrition bias” and “report-
ing bias” which relate to incomplete outcome data and
selective reporting. The domain “other bias” relates to
any potential sources of bias which are not covered by
the aforementioned categories, for example, contamin-
ation between intervention and control groups or bias
arising from particular study designs (e.g. lack of wash-
out period in a cross-over trial).
Data analysis
Extracted data was synthesised descriptively based on
published data only. The data presented in the included
studies were reviewed critically by the authors, taking
into account the outcome of the risk of bias assessment
when synthesising the evidence. Meta-analysis would
have been undertaken according to the predefined
protocol, if two or more studies were sufficiently similar
in methodology to result in a meaningful outcome.
However, included studies used heterogeneous methods
specifically relating to the measurement of outcomes
and intervention delivery, and hence, a meaningful
quantitative analysis was not possible in this instance.
Results
The systematic literature search returned 1848 citations;
after de-duplication, 1378 studies were screened, and 10
met all criteria for inclusion in this review (Fig. 1). One
study was identified via a search of online clinical trials
registries and was deemed to be relevant for inclusion;
however, it is still ongoing and no data were available for
this review [34]. Included studies originated from six dif-
ferent countries and were dated from 1989 to 2016. Of
these, two studies were available in abstract form only
despite attempts to contact the original authors for fur-
ther details [35, 36]. Characteristics of the included stud-
ies can be seen in Table 1. Overall, the pool of included
studies comprised of eight RCTs [35–42], a randomised
crossover trial [43] and a controlled clinical trial [44].
Study participants were people with COPD with average
age above 60 years for all.
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Risk of bias assessment
The overall quality of the included studies was assessed
as average to poor, despite the majority of studies being
randomised controlled trials. This was mainly due to
inadequate reporting of methodology, which gave many
studies an unclear risk of bias. There was a low risk of
bias with regard to the randomisation and sequence
generation. When it was specified, participants were
usually randomised in 1:1 ratio blocks and one study
randomised using the Latin square design. One study
[44] had a high risk of bias for this domain as there was
a change to protocol during the study, such that ran-
domisation was not possible. Blinding was performed
variably among the studies, with many studies having
incomplete blinding or open label testing. Studies
where only the abstract was available were particularly
susceptible to incomplete or brief descriptions of meth-
odology. Risk of bias for individual studies is presented
in Fig. 2, and a summary of risk of bias is presented in
Fig. 3.
Included studies were of small sample size (range n =
15 to n = 86), and justification for sample size and rele-
vant power calculations were not reported in the publi-
cations across the board.
Treatment failure
Although treatment failure was the primary outcome of this
review, only two studies [41, 42] reported it, with heteroge-
neous research methodologies; thus, meta-analysis was not
possible. One of these studies, with 50 participants,
Fig. 1 PRISMA study flow diagram of included studies
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demonstrated a similar rate of treatment failure with oral/
metred dose inhaler (MDI) (32%) and intravenous (IV)/
nebuliser (33%) (P = 1.0) [41]. However, these treatment
failures were considered to be minor (defined as a subject-
ive perception of clinical deterioration by either participant
or physician) and did not satisfy the definition stated in the
protocol of this review. The other study [42] noted inci-
dences of treatment failure as defined by our criteria; how-
ever, these participants were withdrawn from the original
sample of 48 and excluded from analysis. Despite this, the
authors reported treatment failure as one of their outcomes
in their description of methods. In the case of different
treatment regimes, IV/aerosol therapy resulted greater ICU
admissions compared to oral/MDI (3 vs 1) [42].
Forced expiratory volume in 1 s
Of the 10 included studies which reported FEV1 as an
outcome, nine reported that all groups experienced an
increase from baseline with administration of SABD
[36–44]; the improvement from baseline could not be
determined from one of the included abstracts [35].
None of the studies reviewed showed a significant differ-
ence between groups for FEV1 regardless of variances in
types of SABD, delivery method or dose [35, 40–44].
However, for one study (n = 42), authors reported a
non-significant average increase in FEV1 of 11.2% with
10 mg of salbutamol versus 6.9% with 5 mg [44]. An-
other study, with 86 participants, demonstrated higher
percentage increase in FEV1 at 120 min compared to
baseline with a higher dose regimen of albuterol (29.2 ±
35.9 vs 15.1 ± 36.2; P = 0.09) though again this was
non-significant [37]. From one small RCT (n = 20), use
of a nebuliser appeared to improve the percent change
in FEV1 at 1 h post-treatment compared to MDI plus
spacer (16.7% ± 17.0 vs 13.4% ± 20.5). However, authors
reported that this was a non-significant and both groups’
improvements appear to be clinically relevant compared
to pre-treatment values [43].
Forced vital capacity
Of the 10 included studies, seven reported FVC as an
outcome, all of which reported an improvement from
baseline regardless of group.
Four studies reported a statistically significant difference
between intervention and control groups. Salbutamol at
10 mg compared to 5 mg was reported to have signifi-
cantly improved FVC at 10 min post-administration; al-
though the exact p value was not reported for this time
point, the magnitude of difference between the two groups
was approximately 11.5% [44]. However, after 10 min, au-
thors reported the statistical significance of the between
groups difference was not sustained for subsequent time
points up to 240 min [44]. Other studies investigating dif-
ferent dosing approaches did not report any evidence of
an effect on FVC with a higher versus lower dose [37, 40].
Both of these studies had a sample size of 86 and were the
two largest studies included for review.
In a study of 62 people with COPD, monotherapy (sal-
butamol 5 mg) alone compared to combination therapy
(salbutamol 5 mg plus ipratropium 500 μg) demonstrated
a significantly higher mean change in FVC at 3 days
post-administration (0.25 L (0.42) vs 0.04 L (0.41), 95% CI
− 0.42 to 0.001; P = 0.05); this difference was no longer sig-
nificant on days 7, 14 and discharge [39].
In terms of delivery method, continuously nebulised
albuterol (− 0.85% ± 73.38) appeared inferior to intermit-
tently nebulised albuterol (21.22% ± 30.73) for percent-
age change in FVC at 4 h, P = 0.043, reported as
absolute change in FVC [35]. Nebulised albuterol
Fig. 2 Risk of bias assessment for individual included studies
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resulted in a higher mean change in FVC 1 h after treat-
ment (310 mL ± 370) compared to albuterol via MDI
plus spacer (190 ± 360); however, this difference was not
significant [43]. Furthermore, vibrating mesh nebuliser
(salbutamol 2.5 mg plus ipratropium 0.5 mg) demon-
strated a greater increase in FVC (0.40 L ± 0.39) compared
to standard hospital jet nebuliser (same drug regime)
(0.19 L ± 0.19); however, this was not significant, P = 0.06.
A subsequent study reported that the addition of a spacer
and/or an increase in dose from 1.0 to 2.5 mg (terbutaline)
did not confer any additional benefit to FVC [38]. A differ-
ing treatment regime including nebulised salbutamol plus
ipratropium compared to fenoterol plus ipratropium via
MDI with spacer also failed to demonstrate a difference
between the groups [42].
Dyspnoea
Dyspnoea was reported in six of the included studies:
four utilising the Borg scale [36, 41, 43, 44] while the
remaining two studies [39, 42] used subjective descrip-
tion including visual analogue scale. All six studies dem-
onstrated improvement in dyspnoea post-intervention
compared to baseline. The only study investigating dif-
fering doses found no difference between administration
of 5 mg or 10 mg of salbutamol [44].
Similarly, the two studies that investigated oral/MDI
versus IV/nebuliser showed no significant differences be-
tween groups with P = 0.75 [41] and P = 0.15 [42] re-
spectively. There was a greater change in dyspnoea
measured by Borg scale when MDI plus spacer albuterol
was administered (− 1.08 ± 2.01) compared to nebulised
albuterol (− 0.73 ± 1.75), but this did not reach statistical
significance [43]. Another study comparing two different
types of nebulisers (vibrating mesh versus standard hos-
pitalised jet) showed no statistical difference between
group comparison [36]. The addition of ipratropium to
nebulised salbutamol was not found to be more effective
in reducing self-reported dyspnoea than nebulised salbu-
tamol alone [39].
Sputum production/purulence
None of the included studies evaluated effect of SABD
on sputum production or purulence.
Quality of life
Only one study reported on quality of life as an outcome.
Using the chronic respiratory disease index questionnaire
[42], the study did not demonstrate a significant difference
when comparing oral/MDI versus IV/nebuliser (86 ± 20 vs
90 ± 24, P = 0.73) for this outcome. However, both groups
improved in quality of life from baseline regardless of
intervention; the IV/nebuliser group by approximately
20% (P = 0.036) and the oral/MDI group by approximately
45% (P = 0.0069).
Adverse events
Five of the included studies reported adverse events re-
lating to β2-agonists including changes to heart rate [40,
41, 43, 44], palpitations [40], tremor [40, 44] and
changes to blood pressure [43, 44]; one study reported
on albuterol-related side effects as a general outcome
without further qualification [37]. One study found no
difference between 2.5 mg and 5 mg of albuterol [40]
with regard to heart rate and palpitations, but tremor
was common with the higher dose (5 mg). This study re-
ported overall adverse events were similar in both
groups (P = 0.506) [40]. Another study comparing 10 mg
salbutamol versus 5 mg salbutamol demonstrated higher
increase in heart rate with 10 mg salbutamol dose at
30 min post-administration (76.9 ± 4.3 versus 74.7 ±
3.27 bpm). While this was reported as significant, there
was no supporting p value [44]. Salbutamol 10 mg led to
an earlier maximal change in heart rate (t = 30 min)
compared to salbutamol 5 mg (t = 120 min). Further-
more, there was a significant decrease in systolic blood
pressure in the 10 mg salbutamol at t = 10 min (10.2 ±
13.7 mmHg). Similarly, diastolic blood pressure was also
significantly lower with 10 mg salbutamol compared to
baseline, reaching nadir t = 30 min; 5 mg salbutamol also
Fig. 3 Risk of bias summary for included studies
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significantly decreased from baseline, but the reduction
occurred later at t = 60 min and the minimum was
smaller (5.8 ± 2.0 mmHg versus 10.2 ± 1.7 mmHg). Area
under curve for tremor was greater in the 10 mg salbu-
tamol (1139.9 ± 95.5) compared to 5 mg salbutamol
(892.4 ± 61.0), p value not reported [44]. A study looking
at cumulative dose of 15 mg versus 10 mg albuterol
showed significantly higher adverse events in the higher
cumulative dose (45% versus 24%) (P < 0.05). However,
this study did not specify the type of adverse events
other than to say “side effects consistent with albuterol
treatment” [37].
There was no difference in heart rate (2.7 ± 9.0 bpm
versus 2.9 ± 7.4 bpm) with administration of SABD via
MDI plus spacer or nebuliser [43]. Similarly, there was
no difference in systolic/diastolic blood pressure 5 min
post-treatment with MDI plus spacer (2.7 ± 11.8/2.5 ±
12.5 mmHg) compared to nebuliser (0.8 ± 15.2/3.7 ±
13.2 mmHg) [43].
In a single study where participants received therapy
via either oral/MDI or IV/nebuliser regime (n = 50),
there was no significant difference reported between
groups in terms of heartrate post-treatment [41]. Any
differences noted by the authors, from baseline, were
consistent with an expected physiological response to
SABD administration (i.e. increase < 10 bpm) [41].
The only study reporting use of ipratropium did not
report adverse events [39].
Hospital utilisation
Six of 10 studies investigated hospital utilisation as an
outcome [37, 39–43].
The study comparing cumulative higher dose re-
gime to lower overall dose resulted in equal rates of
hospitalisation (69% for both groups) [37]. The
addition of ipratropium to salbutamol did not im-
prove the hospital length of stay in one study [39].
However, it appears administering an oral/MDI
SABD treatment regime compared to an IV/nebuliser
regimen may have some (though non-significant) re-
ductive effect on length of stay (10.6 ± 2.8 vs 15.5 ±
10.3, P = 0.06) [42].
Dosing with 2.5 mg versus 5 mg of albuterol produced
a reduced length of stay (6 vs 9 days) though this was
not statistically significant (P = 0.084) [40]. Adding ipra-
tropium to salbutamol resulted in additional, though
non-significant, mean length of stay: 11.8 ± 4.4 vs 10.5 ±
4.7 days (95% CI − 1.02 to 3.62) (P > 0.05) [39]. Two
studies demonstrated a reduced but non-statistically sig-
nificant length of stay with an oral/MDI with spacer
treatment regime (antibiotics, steroids and SABD) com-
pared to IV/nebuliser 11 ± 3 versus 16 ± 10 days (P =
0.06) [42] and 4.3 vs 5.1 days (P < 0.56) [41].
A 5-mg vs 2.5-mg regimen of albuterol resulted in
higher cumulative cost £8665 versus £4048 (£188.37 vs
£101.20 per patient) [40].
Only one study reported hospital readmissions as an out-
come, following up participants 20 weeks post-discharge
[42]. At this time, 42% of the 23 participants (approximately
10 individuals) in the IV/nebuliser treatment group experi-
enced a readmission versus 66% of 25 participants (17 indi-
viduals) in the oral/MDI with spacer treatment group.
Discussion
Established guidelines for the management of COPD ex-
acerbations recommend the use of SABD [7, 23]. The ef-
fectiveness of SABD in stable COPD is well established
[45, 46], and it is this evidence that has been generalised
for use in the inpatient setting [47–50]. However, in-
patient administration of SABD is underpinned by weak
evidence and is not specific to patients with AECOPD
[7, 22, 23]. As such, this review aimed to evaluate the
existing evidence for the effectiveness of SABD for pa-
tients admitted to hospital due to AECOPD. A paucity
of data was identified with only 10 studies meeting the
eligibility criteria for inclusion, the majority of which
had small sample size, poor methodological quality and/
or lacked adequate reporting of the study design. This is
likely a reflection of looser reporting standards for older
studies (only one included study was published after
2005). Further, there appears to be a lack of interest
within the clinical and research space toward focussing
new endeavours and funding on what is widely consid-
ered a well understood, mainstream treatment for
AECOPD. However, as evidenced by the findings of this
review, there are still gains to be made particularly for
outcomes relating to hospital utilisation, spending and a
baseline for standardisation of care. The prevalence of
COPD and subsequent high levels of hospitalisations
warrant a renewed interest in this fundamental area of
inpatient management of these patients [51]. Through
evaluation of patient and hospital-based outcomes, we
attempted to determine the optimal dose, delivery
method, duration and types of agents for the hospital
setting, as described in the proceeding sections.
Dose evaluation
Comparison of dosages of SABD for inpatient applica-
tion demonstrated no added clinical bronchodilatory
benefit with doses above 2.5 mg of salbutamol per ad-
ministration [35, 40, 44]. In fact, there was some indica-
tion that a higher dose may result in a higher number of
adverse events, with hypotensive and arrhythmic effects
noted with > 10 mg of salbutamol [44]. This finding is
consistent with a recent study demonstrating a positive
correlation between blood salbutamol levels and
N-terminal prohormone of brain natriuretic peptide in
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people treated with rescue relief for AECOPD [20]. Fur-
thermore, this review indicates that with 5 mg, there
was a trend towards increased incidence of tremors,
though this was not significant [40]. The evidence sug-
gests that using a lower dose of SABD (e.g. salbutamol
2.5 mg) is just as effective as a higher dose (e.g. 5 mg) in
achieving relief of symptoms of breathlessness associated
with AECOPD and may prevent unnecessary risk to pa-
tients due to drug-related adverse events. Moreover, the
use of less medication may potentially result in cost sav-
ings with reduced dose delivery per patient for the same
clinical benefit [40].
Similarly, the sole study looking at terbutaline did not
confer additional benefit beyond dose of 1 mg compared
to 2.5 mg [38].
Delivery method
Of the five studies [36, 38, 41–43] reporting different de-
livery methods for SABD, two were embedded into a
wider treatment regime [41, 42]. Both of these studies
used a similar approach, differing mainly in the use of
either IV or oral steroids [42] or IV/oral antibiotics [41].
The combination of IV steroid with nebulised SABD is
likely a model for treating a high-dependency patient re-
quiring more support than a patient who can tolerate an
oral steroid and navigate an MDI with spacer [42]. While
consistent use of either oral or IV steroid would have been
preferable in methodological terms for clarity of compari-
son, unpacking the results of this study with reference to
other research offers interesting and practical insights into
clinical decision-making across the diverse spectrum of
patients. A systematic review concluded that in the treat-
ment of AECOPD, there is no discernible difference be-
tween treating with and IV or oral steroid approach [52].
Furthermore, a recent Cochrane Review concluded, much
like the results of this review, that while there is a dearth
of large well-conducted studies in this area, there does not
appear to be a difference between treating with nebulised
or MDI with spacer SABD when considering FEV1 [53].
The lack of conclusive results in favour of one or the other
suggests that clinicians can feel comfortable using which
ever delivery method best suits the needs and capabilities
of their individual inpatients. One study investigated MDI
with spacer versus nebulised SABD with both groups re-
ceiving equivalent standard therapy which included use of
IV aminophylline and corticosteroids and additional oral
or inhaled sympathomimetics [43]. The standard therapy
outlined in the latter study is now considered outdated
and no longer considered standard practice.
Overall, despite variations in methodology, all five
studies demonstrated no significant difference between
delivery of SABD via either nebuliser or MDI with spa-
cer. In this instance, clinicians may be guided more by
the patient presentation and tolerability when determin-
ing which device to use, rather than potential efficacy of
the device.
Duration of treatment
No studies investigated the optimal time frame for dur-
ation of SABD administration before termination in the
inpatient setting for AECOPD. This is an important as-
pect of the treatment regime and requires further
investigation.
Mono- versus co-intervention therapy
All studies showed an improvement from baseline with
administration of SABD; this is not surprising given estab-
lished evidence of effectiveness in stable COPD [46].
There appeared to be no difference between mono- and
co-intervention therapy with regard to FEV1. As a result
of these findings, it is possible to suggest that monother-
apy with a β2-agonist for inpatients with AECOPD to be
sufficient and addition of anticholinergic agents is of no
additional clinical benefit and a potential waste of re-
sources. However, this is based on a single included study
with only 62 participants, and as such, results should be
interpreted with caution. Further research in this area is
required prior to considering changes to practice.
Type of short-acting β2-agonist
Most included studies reported the use of either salbuta-
mol or albuterol which are the same agent [35, 39–41,
43, 44]. One study investigated a treatment regime
which delivered albuterol to one group and fenoterol to
the other group [42]; while both are short-acting
β2-agonists, the latter has a slightly longer duration of
action [54]; another study examined terbutaline [38].
There appeared to be no difference between agents used.
Interestingly, fenoterol has been withdrawn from the
pharmaceutical market due to its association with in-
creased risk of death [55]. Based upon this observation,
a choice may be made according to clinical preference,
safety profile and drug availability.
Limitations of this review
The limitations of this review owe mainly to the quality
and quantity of included studies. The majority of the in-
cluded studies were published before 2008, bar one [36].
Hence, recommendations based on these findings may
not be a true reflection of current clinical practice. This
is perhaps an indication that clinical practice is evolving
quickly, with research and the evidence-base lagging be-
hind. Furthermore, the wider literature on this general
topic is also somewhat lacking in recency; it appears that
perhaps the profession has just accepted SABD as a rela-
tively non-threatening and straight forward treatment
for AECOPD and is happy to focus research efforts on
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other, more exciting things. This is of concern given that
administration of SABD is considered a core therapy
during AECOPD and standardisation of practice is desir-
able. The heterogeneity of reported methodologies and
outcomes made meta-analysis of the data impossible.
Furthermore, as indicated by the risk of bias assessment,
the included studies were of average to poor methodo-
logical quality with small sample sizes, again limiting
generalisability of the findings. It is also desirable to be
able to assess the pooled effect of these studies to be
able to provide a more objective assessment of effective-
ness through meta-analysis; however, this was precluded
in this review.
Recommendations for clinical practice and future
research
Given that a clear clinical benefit was not identified with
use of higher doses of SABD, it is important to consider
the risk of frequent and sustained use, while questioning
continued acceptance of the status quo. A moderated
approach is recommended, especially when administer-
ing four hourly nebulisations; extra care in the case of
people with known or possible unknown comorbid car-
diac disease is necessary as in these patients, risk may
outweigh benefit.
Methodologically rigorous evaluations are required
that evaluate the current use of SABD in the hospital
setting following patient admission for AECOPD, par-
ticularly given the lack of recent evidence identified in
this review. Future studies should report on all the out-
comes pre-specified in this review, as these outcomes re-
flect not only patient level variables, but also those
necessary for policy and guideline decision-making. De-
tailed description of dose, delivery method, duration and
types of agents need to be described in detail to facilitate
accurate evidence-based recommendations for the use of
SABD in the inpatient setting.
Conclusion
Despite the routine use of SABD in the hospital setting for
the management of AECOPD, a paucity of data pertaining
to the inpatient applications of this medication was found.
Though the evidence is limited, it appears consideration of
the use of a single short-acting β2-agonist such as salbuta-
mol/albuterol at a dose of 2.5 mg may be sufficient to get
the desired clinical outcome. Co-intervention therapy and
higher dose regimens were not associated with any discern-
ible clinical benefit for the outcomes reported in this re-
view. Delivery method may be prescribed based on patient
preference given the equivalence observed in delivery
method for available data. However, despite the somewhat
interesting results presented in this review, interpretation
should be made with care as the quality of the evidence
underpinning these outcomes were overall low.
The gap in evidence highlights the need for methodo-
logically rigorous, appropriately powered studies to ad-
dress the use of SABD specifically in the inpatient setting,
to allow for improved patient- and hospital-based out-
comes, and the basis of standardised practice with regard
to prescription of mainline therapy of AECOPD.
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